Vulvovaginal Candidiasis Therapeutic Pipeline and Development Review H1 2015 Research Report
Summary
RnRMarketResearch.com adds "Vulvovaginal Candidiasis - Pipeline Review, H1 2015" therapeutic market research report of 48 pages with latest updates, data and information to its online business intelligence library. This report is complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. Featured News & Press Releases cover by this report includes: Sep 10, 2014: Data for Viamets VT-1161 Presented at ICAAC 2014; Jul 10, 2014: Viamet Reports Additional Positive Interim Results of Phase 2 Study of VT-1161 in Patients with Moderate to Severe Acute Vulvovaginal Candidiasis; Feb 18, 2014: Viamet Reports Positive Interim Results of Phase 2 Study of VT-1161; Sep 24, 2013: Viamet Pharmaceuticals Expands Phase 2 Clinical Program with Novel Antifungal Agent VT-1161; Sep 05, 2013: Viamet Pharmaceuticals Initiates Phase 2 Clinical Program with Novel Antifungal Agent VT-1161; Aug 08, 2012: Ferrer Submits IND For Arasertaconazole Nitrate For Vulvovaginal Candidiasis; Jan 17, 2012: Pevions Therapeutic Candida Vaccine Generates Functional B Cell Memory In All Vaccinees; Oct 11, 2011: Pevions Therapeutic Candida Vaccine PEV7 Shows Robust Systemic And Mucosal Immunogenicity; Sep 01, 2011: Pevion Grants CSL Option Right To Therapeutic Candida Vaccine; Nov 11, 2010: Pevion Announces Positive Preliminary Results From Phase I Study Of PEV7 In Recurrent Vulvovaginal Candidiasis. The scope of the report ranges from global therapeutic landscape of Vulvovaginal Candidiasis to the recent news and deals undertaken in the field of pipeline review. The report also helps in developing and designing in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.